Kyowa Kirin Co Ltd 2023 Integrated Report
The report describes Kyowa Kirin's strong FY2023 performance, including revenue of ¥442.2 billion and record profit attributable to owners of parent of ¥81.2 billion. It highlights the acquisition of Orchard Therapeutics and expanded proprietary sales of Crysvita in North America as important growth developments. Environmental progress includes approximately 55% lower annual CO2 emissions, supported by renewable energy deployment. The report also emphasizes human-capital development and the plan to raise women in management positions to 18% by 2025.
Company: Kyowa Kirin Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2023
Type: Integrated Report
Pages: 67
Back to company
Kyowa Kirin Co Ltd
Integrated Report
The report describes Kyowa Kirin's strong FY2023 performance, including revenue of ¥442.2 billion and record profit attributable to owners of parent of ¥81.2 billion. It highlights the acquisition of Orchard Therapeutics and expanded proprietary sales of Crysvita in North America as important growth developments. Environmental progress includes approximately 55% lower annual CO2 emissions, supported by renewable energy deployment. The report also emphasizes human-capital development and the plan to raise women in management positions to 18% by 2025.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 2023 - Dec 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women on Board
Women in Management
Net Zero Target
Employees